Oncology · Small molecule (oral, once daily)

Zanzalintinib

Zanzalintinib is an oral tyrosine kinase inhibitor from Exelixis. Combined with atezolizumab, it improved overall survival versus regorafenib in refractory colorectal cancer, and the FDA's decision on it is now due March 3, 2027.

Not yet approvedFDA decision for metastatic colorectal cancer extended to March 3, 2027 after a major amendment (company-reported)

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperExelixis
Drug typeSmall molecule (oral, once daily)
TargetMultiple tyrosine kinases
MechanismA multitargeted tyrosine kinase inhibitor that blocks several growth-signaling enzymes inside cancer cells
Other namesXL092

Key points

  • In the 901-patient STELLAR-303 trial, zanzalintinib plus atezolizumab improved overall survival versus regorafenib in previously treated colorectal cancer: 10.9 versus 9.4 months (hazard ratio 0.80).
  • In the prespecified subgroup without liver metastases, the overall survival difference was not statistically significant at the interim analysis (HR 0.79; p = 0.087).
  • Grade 3 or worse treatment-related adverse events were more common with the combination: 60% versus 37%.
  • The FDA's decision date moved from December 3, 2026 to March 3, 2027 after Exelixis submitted updated data that the FDA deemed a major amendment (company-reported).
  • Phase 3 trials are also testing zanzalintinib in kidney cancer and neuroendocrine tumors.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Colorectal cancer
NDA for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer; review extended three months (company-reported). STELLAR-316 is recruiting (registry).
Submitted (FDA decision due March 3, 2027; company-reported)6
6 active · 0 completed
90.6% eventual approval
Application → approval: 90.6%
Kidney cancer (renal cell carcinoma)
Includes STELLAR-304 and LITESPARK-033 in kidney cancer (registry).
Phase 310
9 active · 0 completed · 1 stopped
52.4% eventual approval
Phase 3 → application: 57.8%
Neuroendocrine tumors
STELLAR-311 in neuroendocrine tumors is recruiting (registry).
Phase 2/32
2 active · 0 completed
15.1% eventual approval
Phase 2 → Phase 3: 28.9%
Other cancers
Includes STELLAR-305 in head and neck cancer and other studies (registry).
Phase 2/324
22 active · 0 completed · 2 stopped
15.1% eventual approval
Phase 2 → Phase 3: 28.9%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What zanzalintinib is

Zanzalintinib is an oral tyrosine kinase inhibitor developed by Exelixis. Tyrosine kinases are enzymes that relay growth signals inside cells, and the STELLAR-303 investigators describe zanzalintinib as a multitargeted inhibitor of them. In colorectal cancer it is being developed in combination with atezolizumab, an immunotherapy that blocks PD-L1.

Clinical evidence: STELLAR-303

STELLAR-303 randomized 901 patients with refractory metastatic colorectal cancer, whose disease had progressed after standard chemotherapies, to zanzalintinib plus atezolizumab or to regorafenib, an existing oral option. Results were published in The Lancet in 2025:

Measure Zanzalintinib + atezolizumab Regorafenib
Median overall survival (all patients) 10.9 months 9.4 months
Overall survival hazard ratio (all patients) 0.80 (p = 0.0045)
Overall survival hazard ratio (no liver metastases, interim) 0.79 (p = 0.087, not significant)
Grade 3 or worse treatment-related adverse events 60% 37%

The trial met its primary goal in the full population: a 20% reduction in the risk of death. The absolute gain in median survival was about six weeks, and serious side effects were notably more common.

Regulatory status

Exelixis submitted a New Drug Application in December 2025 for patients whose metastatic colorectal cancer had progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (and, for RAS wild-type tumors, an anti-EGFR therapy). The FDA accepted it under standard review with a December 3, 2026 target date (company-reported).

On September 10, 2026, Exelixis disclosed that the FDA had extended the review by three months, to March 3, 2027. The company had submitted updated safety and efficacy data in response to an FDA request, and the FDA deemed it a major amendment (company-reported, Form 8-K).

Scientific perspective

STELLAR-303 is a useful case study in statistical versus clinical significance. The survival benefit is statistically robust in the full population, but modest in absolute terms, comes with more toxicity, and was not significant in a prespecified subgroup. Regulators approve drugs on the balance of benefit and risk, so a modest benefit in a setting with few options can still support approval. See What Is Statistical Significance in Clinical Trials?

Development perspective

  • Next milestone: the FDA decision, due March 3, 2027. A review extension after a major amendment is a procedural step, not a rejection. Historically, about 90.6% of applications that reach the FDA are eventually approved; that is an industry average, not a prediction.
  • Pipeline: Phase 3 programs in kidney cancer (including STELLAR-304) and neuroendocrine tumors could extend the drug beyond colorectal cancer.
  • Company context: Exelixis describes zanzalintinib as its lead clinical asset (Form 10-Q).

Development timeline

  1. Sep 7, 2022STELLAR-303 begins randomizing patients. Peer-reviewed
  2. Oct 20, 2025STELLAR-303 published: overall survival 10.9 vs 9.4 months with regorafenib (HR 0.80). Peer-reviewed
  3. Dec 2025Exelixis submits a New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. Company-reported
  4. Jan 2026FDA accepts the application under standard review, with a December 3, 2026 target date. Company-reported
  5. Sep 10, 2026FDA extends the review by three months to March 3, 2027 after deeming updated data a major amendment. Company-reported

What could change the outlook

  • The FDA decision, now due March 3, 2027 (company-reported).
  • How the FDA weighs the modest survival gain against higher toxicity, and the non-significant result in patients without liver metastases.
  • Kidney cancer Phase 3 results, including STELLAR-304, whose primary completion the registry estimates for December 2026.
  • STELLAR-316, a Phase 3 colorectal cancer trial run with Natera and Merck (company-reported).

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Zanzalintinib. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedOct 29, 2026

    Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

    “Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael M.

    Company
    Exelixis, Inc.
    Source
    SEC Form 8-K · Financial results
  2. RegulatoryCompany-reportedSep 11, 2026

    Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for...

    zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months.

    Company
    Exelixis, Inc.
    Source
    SEC Form 8-K · Other events
  3. Quarterly reportCompany-reportedAug 5, 2026

    Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

    “For zanzalintinib, our next potential franchise molecule, the R&D organization is executing on our priority goals for pivotal data readouts, clinical trial enrollment and new study initiations, while also laying the foundation for the next wave of development opportunities.

    Company
    Exelixis, Inc.
    Source
    SEC Form 8-K · Financial results

All Zanzalintinib disclosures in Pipeline News

Clinical trials

51 registered trials list Zanzalintinib as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Colorectal cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Phase 3Enrolling by invitation5,000 (est.)May 31, 2030 (est.)No
STELLAR-303 · NCT05425940
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Phase 3Active, not recruiting901Jun 16, 2026No
STELLAR-316 · NCT07750158
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Phase 3Recruiting600 (est.)Apr 5, 2030 (est.)No
NIMBLE · NCT07677579
NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer
Phase 2Not yet recruiting26 (est.)Aug 30, 2028 (est.)No
2 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
STELLAR-002 · NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Phase 1Recruiting1,394 (est.)Jan 31, 2027 (est.)No
STELLAR-001 · NCT03845166
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Phase 1Active, not recruiting325Aug 31, 2026 (est.)No

Kidney cancer (renal cell carcinoma)

TrialPhaseStatusEnrollmentPrimary completionResults posted
LITESPARK-033 · NCT07227402
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Phase 3Recruiting904 (est.)Feb 27, 2032 (est.)No
NCT07489495
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Phase 3Recruiting758 (est.)Nov 27, 2030 (est.)No
STELLAR-304 · NCT05678673
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Phase 3Active, not recruiting317Dec 15, 2026 (est.)No
NCT07049926
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Phase 1/2Recruiting140 (est.)Oct 26, 2031 (est.)No
EXACT · NCT06863311
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Phase 2Recruiting70 (est.)Dec 31, 2027 (est.)No
EXPLORE-RCC · NCT06794229
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
Phase 2Recruiting69 (est.)Jun 6, 2028 (est.)No
NCT07691476
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
Phase 2Not yet recruiting48 (est.)Oct 31, 2028 (est.)No
NCT07578025
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Phase 2Not yet recruiting34 (est.)Jun 24, 2028 (est.)No
ZAMBONI · NCT07043608
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Phase 2Recruiting20 (est.)Apr 30, 2029 (est.)No
1 Phase 1 or other early-stage study
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06191796
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Why stopped (registry): The study was terminated prior to starting the Phase 2 portion due to a business decision.
Phase 1Terminated25May 12, 2025No

Neuroendocrine tumors

TrialPhaseStatusEnrollmentPrimary completionResults posted
STELLAR-311 · NCT06943755
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2/3Recruiting440 (est.)Jun 30, 2029 (est.)No
NCT06926634
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Phase 2Recruiting32 (est.)Dec 31, 2034 (est.)No

Other cancers

TrialPhaseStatusEnrollmentPrimary completionResults posted
STELLAR-305 · NCT06082167
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2/3Active, not recruiting600 (est.)Aug 2028 (est.)No
Morpheus Lung · NCT03337698
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Why stopped (registry): Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
Phase 1/2Terminated314Oct 14, 2025Yes
STELLAR-202 · NCT07845786
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2Recruiting60 (est.)Jun 15, 2028 (est.)No
NCT07042919
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Phase 1/2Recruiting59 (est.)Mar 4, 2029 (est.)No
ZANACC · NCT07682675
Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck
Phase 2Not yet recruiting51 (est.)Apr 2029 (est.)No
NCT06959511
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Phase 2Recruiting45 (est.)Mar 1, 2028 (est.)No
ZENOBIA · NCT06698250
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2Recruiting40 (est.)Dec 31, 2026 (est.)No
NCT07511504
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
Phase 2Not yet recruiting40 (est.)Aug 1, 2027 (est.)No
NCT06937866
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Phase 1/2Recruiting38 (est.)Mar 2030 (est.)No
NCT07878689
Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
Phase 1/2Not yet recruiting36 (est.)Dec 1, 2028 (est.)No
NCT06959641
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2Recruiting33 (est.)Sep 11, 2028 (est.)No
PRO-XL · NCT06568562
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 2Recruiting32 (est.)Dec 2026 (est.)No
NAPOLEON · NCT07218666
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
Phase 2Recruiting30 (est.)Jul 2028 (est.)No
ZENITH · NCT07623460
Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
Phase 2Not yet recruiting30 (est.)Sep 2028 (est.)No
NEO COMBAT XL · NCT07484139
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
Phase 2Recruiting26 (est.)May 2028 (est.)No
NCT07608718
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 2Not yet recruiting19 (est.)May 2029 (est.)No
NCT07226063
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Phase 2Not yet recruiting16 (est.)Feb 2028 (est.)No
NCT07470489
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
Phase 2Recruiting12 (est.)Sep 1, 2030 (est.)No
NCT07185945
Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
Why stopped (registry): Funder withdrew
Phase 2Withdrawn0Jun 2027 (est.)No
5 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06952010
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Phase 1Recruiting303 (est.)May 31, 2027 (est.)No
NCT06795009
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase 1Recruiting36 (est.)Nov 30, 2029 (est.)No
NCT06912087
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Phase 1Recruiting36 (est.)Jun 5, 2027 (est.)No
NCT07773454
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase 1Not yet recruiting18 (est.)Jul 31, 2028 (est.)No
NEO-COMBATXL · NCT06902376
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1Recruiting12 (est.)Mar 31, 2028 (est.)No

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
STELLAR-201 · NCT07428616
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Phase 2Recruiting100 (est.)Feb 29, 2028 (est.)No
NCT06571734
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Phase 2Recruiting73 (est.)Jul 1, 2028 (est.)No
NCT07193550
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Phase 2Recruiting70 (est.)Oct 31, 2029 (est.)No
NCT07283731
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
Phase 2Recruiting20 (est.)Nov 1, 2028 (est.)No
NCT07527169
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
Phase 2Recruiting16 (est.)Jul 1, 2028 (est.)No
NCT07714551
Zanzalintinib in Unresectable and Progressive MPGGs
Phase 2Not yet recruiting14 (est.)Jan 1, 2031 (est.)No
3 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06962332
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Phase 1Recruiting20 (est.)Dec 2025 (est.)No
NCT06957431
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Phase 1Recruiting18 (est.)May 31, 2031 (est.)No
NCT06968988
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Why stopped (registry): Protocol amendment
Phase 1Suspended18 (est.)Feb 12, 2029 (est.)No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Hecht JR, et al. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. The Lancet. 2025;406(10517):2360–2370.Peer-reviewed
  2. Exelixis. Form 8-K: FDA extends review of zanzalintinib NDA (September 10, 2026).Company-reported
  3. Exelixis. Form 10-Q for the quarter ended April 3, 2026.Company-reported
  4. Exelixis. Form 10-Q for the quarter ended October 2, 2026.Company-reported
  5. ClinicalTrials.gov. STELLAR-303 (NCT05425940).Registry
  6. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.